Ksenija, Merokok
Ksenija, Merokok
106,000+
3,250+ INTERNATIONAL 112+ MILLION
OPEN ACCESS BOOKS AUTHORS AND EDITORS DOWNLOADS
AUTHORS AMONG
BOOKS TOP 1% 12.2%
DELIVERED TO AUTHORS AND EDITORS
MOST CITED SCIENTIST FROM TOP 500 UNIVERSITIES
151 COUNTRIES
1. Introduction
1.1 Cardiovascular disease
Cardiovascular diseases (CVD) are the number one killer of modern humankind. According
to the World Health Organization (WHO) about 17.5 million people die every year from
cardiovascular diseases and it is estimated this number will increase up to 20 million by
2015. Although genetic factors have a significant impact on the cardiovascular disease
occurrence, their importance is often overestimated. The results of numerous clinical and
epidemiological studies emphasise that cardiovascular diseases can often be predicted and
therefore preventable. Accordingly, it is possible to discern several important, independent
disease risk factors wich can be affected to a greater or less extent.
1.1.1 Definition
Cardiovascular diseases are caused by arterial lesions characterized by local intimae
thickening consisting of proliferating, altered smooth muscle cells, macrophages, lipids from
intracellular and extracellular serum lipoprotein deposits and proliferating connective tissue
(collagen, elastin, mucopolysaccharides. Consequential arterial narrowing causes CVD,
stroke, and peripheral arterial disease. The risk factors leading to the development and
occurrence of cardiovascular disease are arterial hypertension, cigarette smoking,
hypercholesterolemia, hypertriglyceridemia, diabetes mellitus and positive family history.
Additional factors favouring the occurrence of cardiovascular disease include obesity,
sedentary lifestyle (insufficient physical activity) and emotional stress. Cardiovascular
diseases are associated with high morbidity and mortality rates, thus posing a major health
and socioeconomic problem to modern society. CVD are the worlds the leading cause of
death and severe disability. CVD or ischemic heart disease occur due to reduction of
coronary blood flow, most commonly caused by coronary thrombus. This results in
myocardial lesions, whose extent determine the symptomatology, clinical course and
disease outcome. According to symptomatology and clinical course, ischemic heart disease
is categorized into acute coronary syndrome (ST-segment elevation myocardial infarction -
STEMI, non-ST-segment elevation myocardial infarction – NSTEMI and unstable angina)
and stable angina pectoris. In almost 99% of cases, CVD are caused by obstructive
atherosclerosis and less frequently by spasm (usually idiopathic, or caused by drugs such as
cocaine). Subintimal plaques reducing or obstructing coronary blood flow characterize
atherosclerosis.
www.intechopen.com
4 Atherosclerotic Cardiovascular Disease
Strict prevention of risk factors in patients with established CVD and those with high-risk
profile can reduce the incidence and recurrence of clinical complications - coronary artery
disease, stroke and peripheral arterial disease. It is crucial to focus on the prevention of
disability and premature death. Coronary atherosclerosis typically develops insidiously; it is
irregularly distributed through vascular bed. Acute coronary syndrome occurs due to
sudden obstruction of blood flow to heart muscle, mainly due to rupture of eccentric
atherosclerotic plaque. Major clinical presentations of coronary heart disease are stable
angina pectoris, unstable angina and myocardial infarction. Risk factors include high levels
of LDL-cholesterol, low HDL-cholesterol level, high triglyceride level, smoking, diet and
lifestyle as well as systemic diseases like arterial hypertension and diabetes. The association
between serum total cholesterol and LDL-cholesterol levels with risk of coronary heart
disease is now well recognized and enduring. HDL-cholesterol is inversely associated with
risk of coronary heart disease. Reduction of serum LDL-cholesterol slows the progression of
coronary heart disease. Reduced LDL-cholesterol was also beneficial in those patients with
existing coronary heart disease even if their LDL-cholesterol is within normal limits.
1.2 Atherosclerosis
Atherosclerosis is pathological process characterized by formation of subintimal plaques
that can reduce or obstruct blood flow through the vessel. It is a result of normal blood
vessels ageing, with initial lesion developing before age 30 (so-called fatty streaks). Risk
factors that significantly accelerate this process are serum lipid impairment, hypertension,
cigarette smoking, diabetes mellitus, obesity, physical inactivity and hereditary factors i.e.
positive family history of cardiovascular disorders. Elevated level of low-density lipoprotein
(LDL) and decreased level of high-density lipoprotein (HDL) strongly predispose the
development of atherosclerosis. As mentioned above, so-called protective HDL-cholesterol
is inversely proportional to the risk of CVD. Main causes of its decrease are cigarette
smoking, obesity and inadequate physical activity. Premenopausal women usually have
higher HDL levels then men due to hormonal effects of estrogen and therefore lower
incidence of CVD. This protective effect vanishes in postmenopause. The cholesterol level
and the incidence of CVD are strongly influenced by environmental factors including diet.
Besides hyperlipoproteinemia, arterial hypertension is another major risk factor for the
occurrence and progression of atherosclerotic lesions. The main pathophysiological
www.intechopen.com
The Importance of Risk Factors Analysis in the Prevention of Cardiovascular Disease (CVD) 5
www.intechopen.com
6 Atherosclerotic Cardiovascular Disease
affects the proximal portions of the renal arteries and carotid bifurcation, in the extracranial
brain circulation. Not all manifestations of atherosclerosis result from stenotic, occlusive
disease. Ecstasies and development of aneurismal disease (pathological widening of blood
vessel), for example, frequently occur in the aorta. In addition to local, flow-limiting
stenoses, non-occlusive intimal atherosclerosis also occur diffusely in affected arteries, as
shown by intravascular ultrasound and postmortem studies.
Atherogenesis in human typically occurs gradually over a period of many decades.
Atherosclerotic plaques growth probably does not occur in a smooth, linear fashion, but
rather discontinuously, with periods of relative quiescence punctuated by periods of rapid
progression. After a prolonged silent period, atherosclerosis may clinically manifest itself in
acute or chronic fashion (stable angina, reproducible intermittent claudicating or acute
coronary syndrome). Some people never experience clinical manifestation of arterial disease
despite the presence of widespread atherosclerosis demonstrated post-mortem.
The endothelial monolayer overlying the intimae contacts blood. Its’ structural and
functional consistency is the first dam for development of atherosclerosis.
Hypercholesterolemia promotes accumulation of LDL-particles in the intimae. The
lipoprotein particles then associate with constituents of the extracellular matrix, notably
proteolytic enzymes. Sequestration within the intimae separates lipoproteins from some
plasma antioxidants and favours oxidative modification. Such modified lipoprotein particles
may trigger a local inflammatory response responsible for signaling subsequent steps in
lesion formation. The augmented expression of various leukocytes adhesion molecules
recruits monocytes to the site of a nascent arterial lesion.
Once adherent, some white blood cells will migrate to the intimae attracted by the factors
including modified lipoprotein particles themselves and chemo attractant cytokines, such as
the chemokine macrophage chemo attractant protein-1 produced by vascular wall cells in
response to modified lipoproteins. Leukocytes in the evolving fatty streak can divide and
exhibit augmented expression of receptors for modified lipoproteins. These mononuclear
phagocytes ingest lipids and become foam cells, represented by a cytoplasm filled with lipid
droplets. As the fatty streak evolves into a more complicated atherosclerotic lesion, smooth-
muscle cells migrate through the internal elastic membrane and accumulate within the
expanding intimae where they lay down extracellular matrix that forms the bulk of the
advanced lesion. Depending on the lipid compound, plaques are divided into stable and
unstable. Stable plaques contain smaller amount of ingested lipids covered with thick
fibrous layer thus preventing its rupture. On the other hand, unstable plaques with high
lipid content and thin fibrous cap are very vulnerable and their rupture initiates acute
ischemic event.
www.intechopen.com
The Importance of Risk Factors Analysis in the Prevention of Cardiovascular Disease (CVD) 7
www.intechopen.com
8 Atherosclerotic Cardiovascular Disease
Main treatment goals are reduction of target organ damage and prevention of
cardiovascular events. Lifestyle changes are recommended to all patients and represent
main stem of therapy in spite of wide spectrum of medications. The Guidelines have kept
their educational and advisory character, emphasizing individual approach to patients, thus
trying to improve implementation in everyday practice.
www.intechopen.com
The Importance of Risk Factors Analysis in the Prevention of Cardiovascular Disease (CVD) 9
www.intechopen.com
10 Atherosclerotic Cardiovascular Disease
Although the relationship varies by age and sex, a 20-mmHg rise in systolic BP or a 10-
mmHg rise in diastolic BP doubles the cardiovascular (CV) risk. Support for this linear
association between increased BP and risk of CV events arise from the results of
hypertension treatment. Meta-analyses of these trial data consistently and clearly show that
BP reduction is effective in reducing CV events. Highly significant and clinically important
reductions of stroke and CHD events and vascular deaths were apparent using these agents.
Interestingly the benefits in terms of CHD events reduction were less than those expected
from prospective observational data. Nevertheless, 10-20 mmHg average reduction in BP
achieved in the trials improves CHD prevention.
2.2 Lipids
Lipids are not water-soluble and their transport in blood is only possible in complexes with
protein-apoprotein. Lipoprotein particles have spherical shape. Their main goal is the
transfer of lipids and fat-soluble vitamins. They consist of hydrophobic core containing
nonpolar lipids (triglycerides and esterified cholesterol) and hydrophilic surface layer of
polar lipids (phospholipids and nonesterified cholesterol).
Apoproteins are located on the surface but their nonpolar part reaches the core particles.
The main metabolic role of apoprotein is to act as a cofactor of some enzymes involved in
the metabolism of lipoprotein particles and to bind to specific receptors on the surface of
various cells and thus facilitate the entry of lipoproteins into them and catabolism of these
particles in the cells. Lipoproteins are divided as follows:
1. Chylomicrons
2. Very low density lipoprotein - VLDL
3. Low density lipoprotein - LDL
4. High density lipoproteins - HDL
5. Intermediate density lipoproteins - IDL
The largest particles - chylomicrons transport triglycerides and cholesterol ingested in meals
from the small intestine to the liver. Bloodstream is abundant with chylomicrons after meal,
especially the one rich and fat. VLDL particles are synthesized in the liver and transport
triglycerides and cholesterol to the heart muscle and adipose tissue. Since VLDL particles
hydrolyze triglyceride and release smaller particles IDL particles during their travel through
bloodstream, they are believed to promote atherosclerosis. LDL particles are the product of
VLDL catabolism and mainly consist of cholesterol. LDL carries cholesterol from the liver
www.intechopen.com
The Importance of Risk Factors Analysis in the Prevention of Cardiovascular Disease (CVD) 11
and blood cells. Excess of cholesterol not used by cells is deposited in artery walls.
Gradually, deposited cholesterol and other substances create plaque, which can eventually
cause a blockage of blood vessel. HDL particles contain more protein than any other
lipoprotein. HDL circulates through the blood and removes excess cholesterol from the
blood and tissues, returning it to the liver from where one can again be incorporated into
LDL. High HDL cholesterol levels are associated with low levels of chylomicrons, VLDL
remnants, LDL and consequently a lower risk of atherosclerosis.
HDL-cholesterol particles are rich in cholesterol, but it is descended from the atherosclerotic
fatty deposits on artery walls where it is in surplus. Therefore, the particles are protective,
preventing the development of atherosclerosis.
Unlike HDL-cholesterol, LDL-cholesterol particles, which also has the highest cholesterol
content are highly atherogenic and play a key role in various stages of atherosclerosis.
Increased amount of LDL-cholesterol in the blood is the most important etiological factor for
the occurrence of coronary heart disease and myocardial infarction. Low HDL-cholesterol is
also an important risk factor. Clinical importance of diagnosing and treating dyslipidemia is
prevention of emergence and development of atherosclerosis and its major clinical forms -
coronary heart disease and myocardial infarction.
Relation between level of cholesterol (especially LDL-cholesterol) and CVD risk is
supported by data from studies of patients with a family hypercholesterolemia.
Heterozygous for this disease usually die in the fifties of myocardial infarction, while
homozygous have even higher cholesterol levels and die from CVD before age 20.
Epidemiological studies in different countries in the world, which include socio-economic
conditions and diet, show a direct correlation between the concentration cholesterol in blood
and mortality from CVD. There is no population with high CVD and overall low cholesterol
level in the blood. In case of exceptions, there are other risk factors for CVD.
It is interesting to notice that the Japanese, who live in Japan on local diet with low
concentration of cholesterol, after migrating to USA, acquire dietary habits of the host
country and their level of blood cholesterol is much greater than in Japan. Consequently, the
incidence of coronary disease is increased.
High triglycerides blood level is also a risk factor for cardiovascular disease, but less
important than hypercholesterolemia.
In contrast to hypercholesterolemia, where CVD risk rises with concentration of cholesterol
in the blood, the biggest risk arises with moderate increase in triglyceride level.
Hypertriglyceridemia is regularly accompanied by a decreased HDL-cholesterol and low
HDL-cholesterol is an important atherosclerotic risk factor, independent of other factors.
VLDL and IDL particles, both rich in triglycerides have atherogenic effect and
hypertriglyceridemia promotes thrombogenesis and inhibits fibrinolysis. Only extremely
severe hypertriglyceridemia (greater than 10 mmol/L) increases risk of acute pancreatitis.
Increase in levels of special types of lipoprotein particles Lipoprotein (a) (Lp (a)) which are
similar in composition to LDL particles, but also containing Apo (a), (intervenes in the
process of thrombogenesis), is an independent risk factor for atherosclerosis.
2.2.1 Dyslipidemia
Dyslipidemia is defined as an abnormal plasma lipid status. Common lipid abnormalities
include elevated levels of total cholesterol, LDL-cholesterol, lipoprotein (a), triglyceride,
HDL-cholesterol and a preponderance of small dense LDL particles. These abnormalities
www.intechopen.com
12 Atherosclerotic Cardiovascular Disease
can be found alone or in combination. Most patients with atherosclerotic vascular disease
have some form of dyslipidemia, even though their total cholesterol may not differ
significantly from normal values. 35-40% of all CVD cases occur in patients with normal
total cholesterol levels (< 5mmol/L, < 190mg/dl).
Total plasma cholesterol level should be below 5 mmol/L (190mg/dl) and LDL-cholesterol
should below 3 mmol/L (115 mg/dl). For patients with clinically established CVD, patients
with diabetes and asymptomatic people at high risk of developing CVD, treatment goals
should be total cholesterol < 4.5 mmol/L (175mg/dl) and LDL-cholesterol < 2.5mmol/L
(100mg/dl).
Treatment for HDL-cholesterol and triglycerides disorders are indicated if HDL-cholesterol
values are < 1.0 mmol/L (<40mg/dl) in men and < 1.2mmol/L (46mg/dl) in women and
fasting triglycerides> 1.7mmol/L (150mg/dl).
Target cholesterol values according to European Guidelines for CVD prevention in clinical
practice:
1. Target cholesterol levels for the general population:
Total cholesterol< 5 mmol/L (190mg/dl)
LDL-cholesterol < 3 mmol/L (115mg/dl)
HDL-cholesterol >1.2mmol/L (46mg/dl) in women and > 1.0mmol/L (40mg/dl) in
men
Triglycerides 1.7mmol/L (150mg/dl) or < 1.7mmol/L (150mg/dl)
2. Target cholesterol levels for patients at high risk:
Total cholesterol < 4.5 mmol/L (175mg/dl)
LDL-cholesterol < 2.5 mmol/L (100mg/dl)
HDL-cholesterol- in women >1.2mmol/L (46mg/dl) and in men>1.0 mmol/L
(40mg/dl)
Triglycerides <1.7mmol/L (150mg/dl)
Studies demonstrate an association between increased concentrations of cholesterol,
especially LDL-cholesterol and advanced atherosclerosis. Association of HDL-cholesterol
levels with atherosclerosis is often underestimated, partly because most studies address the
need for statin therapy.
However noted that the increased concentration of lipoprotein (a), Lp (a), a special kind of
particles that have no metabolic closer ties with other lipoproteins, a risk factor for coronary
heart disease as well as increased LDL-cholesterol. To explains the structural similarity
glycoprotein (a) which is a major apoprotein of these particles with plasminogen and
content of cholesterol and apoprotein B in these particles. These particles can inhibit
fibrinolysis and promote competitive thrombogenesis by inhibiting binding of plasminogen
for its binding sites on endothelium. The importance of risk factors is similar to smoking.
Dyslipidemia is a disorder of lipoprotein metabolism, caused by their excessive or
otherwise, insufficient production. Disturbances characteristic of dyslipidemia include
elevated levels of triglycerides (hypertriglyceridemia), decreased levels of HDL-cholesterol,
elevated levels of LDL-cholesterol, lower LDL/HDL ratio and elevated levels of free fatty
acids. Dyslipidemia is a heterogeneous disorder of complex etiology. The causes of
dyslipidemia may be a primary and secondary. Primary causes include hereditary factors
such as the deficit for the LDL receptor or apoprotein B involved in binding LDL particles to
LDL receptor. In practice, the primary causes account for only a small part of cases, with
predominance of secondary causes such as obesity, high fat intake, physical inactivity,
smoking, diabetes and hypothyroidism.
www.intechopen.com
The Importance of Risk Factors Analysis in the Prevention of Cardiovascular Disease (CVD) 13
www.intechopen.com
14 Atherosclerotic Cardiovascular Disease
sports, but are lower in smokers, overweight and diabetics. The other known risk factors are
also reflected by the individual blood lipid values.
2.2.3 Hyperlipidemia
Hyperlipidemia is a type of lipid disorder consisting of hypercholesterolemia and
hypertriglyceridemia and is marked by increased lipids concentration in the blood. It is
classified in six classes (according to Frederickson). For clinical purpose, it is divided into
primary, or familial hyperlipidemia caused by genetic factors and secondary (acquired)
hyperlipidemia, which arise because of liver disease, diabetes or thyroid gland disorder.
Other important risk factors for the occurrence of secondary hyperlipidemia are the use of
some medications and birth control pills. Although part of hyperlipidemia is due to genetic
reasons, the majority of secondary hyperlipidemias occurs as the effects of lifestyle,
inadequate physical activity and improper and diet. One should borne in mind that, despite
all the pathology caused by hyperlipidaemia, fats are essential for normal functioning of the
organism.
2.2.3.1 Hypercholesterolemia
Hypercholesterolemia or increased blood cholesterol level found in diseases such as
hepatitis, renal disease, hypothyroidism and diabetes. Hypercholesterolemia is often a
consequence of inadequate nutrition, rich in saturated fatty acids. Therefore, dietary
changes, increased physical activity and finally pharmacological therapy are advised for
people with elevated cholesterol levels in blood. Unfortunately, most of the blood
cholesterol is produced in liver so lifestyle changes can lower cholesterol level no more
than 15%. Therefore, therapy in indicated in cases of insufficient results from diet. Studies
show that high levels of total cholesterol and LDL-cholesterol are one of the major causes
of cardiovascular diseases and maintaining proper LDL/HDL ratio reduces the risk of
CVD.
2.2.3.2 Hypertrygliceridemia
Hypertriglyceridemia is elevated level of triglycerides, with normal LDL-cholesterol level.
Hypertriglyceridemia usually occurs as results of poor eating habits and inadequate
physical activity and is common in obese people. Basic recommendation in the triglyceride
lowering diets are reducing fat intake up to 15% of total calories (fatty meat, fried foods,
replacing animal fat with vegetable), reducing the amount of carbohydrates up to 55% of
total daily caloric intake, selection of complex carbohydrates (cereals, pasta, potatoes) and
intake of foods rich in omega-3 fatty acids (fish, fish oil).
2.2.3.3 Combined hyperlipidemia
There are often combined hyperlipidemias with the elevated blood levels of both cholesterol
and triglycerides. It can be result of bad habits and obesity, genetic predisposition or as a
result of certain diseases and condition. It also represents major risk for coronary heart
disease.
www.intechopen.com
The Importance of Risk Factors Analysis in the Prevention of Cardiovascular Disease (CVD) 15
www.intechopen.com
16 Atherosclerotic Cardiovascular Disease
disease and ischemic stroke. Only long-term reduction of glucose level decreases a risk of
atherosclerosis. The men with proven glucose intolerance have even 50% higher risk of
coronary heart disease than men with normal test submission glucose. Risk is even twice
higher in women. Mortality from CVD in diabetic’s disease is ten times higher than in
people who have no diabetes. In diabetic’s hyperlipoprotenemia, particularly
hypertriglyceridemia, is more common, the amount VDLD-particles is higher, more
atherogenic LDL-particles are generated by VLDL-particles degradation and the amount of
protective HDL-particles is reduced. Macrophages phagocytes LDL- particles faster, due to
increased amounts of glucose in the blood promoting non-enzymatic glycosylation, thus
stimulating atherogenesis. Altered metabolisms of glycosaminoglycans in diabetic patients
are also important for the increased incidence of hyperglycaemia-related atherosclerotic
changes. Hyperglycemia, similar to LDL-cholesterol and VLDL-cholesterol in plasma, slows
down the regeneration of endothelial cells, encouraging atherogenesis. Hyperglycemia acts
as oxidant, accelerating oxidation of LDL-cholesterol particles, partially by reducing
concentrations of vitamin C. No enzymatic glucosylation of collagen, accelerated by
hyperglycaemia also stimulates platelet aggregation and thus atherogenesis. Altered
collagen strongly binds LDL-particles. Diabetic platelets synthesize more thromboxane and
endothelial cells syntheses less prostacyclin, also contributing to thrombocyte aggregation.
Elevated concentrations of insulin promote atherogenesis, because insulin stimulates
migration of smooth muscle cells from media into the intimae, their proliferation at the site
of endothelial injury and activity of their receptors for LDL-cholesterol. It is widely known
that many diabetics, particularly those with type 2 are overweight, with hyperinsulinemia
due to peripheral vascular tissue resistance to insulin. Many of them have hypertension,
which also contributes to the rapid atherosclerosis. Glucose intolerance or insulin resistance
and consequent hyperinsulinemia is associated with central obesity type, hypertension,
elevated triglycerides and decreased HDL-cholesterol, making up metabolic syndrome,
which further increases the risk of atherosclerosis. Since diabetics have a much greater, risk
than others patients, diabetic patient with another risk factor, particularly hyperlipidemia,
demands more aggressive approach.
Diabetes mellitus is metabolic disorder characterized by chronic hyperglycaemia with
disturbances of carbohydrate, fat and protein metabolism resulting from defects of insulin
secretion, insulin action or a combination of both. The etiological classification has proposed
by the WHO in 1999. There are 4 specific categories:
1. Type I diabetes characterized by an absolute insulin deficiency of autoimmune or
idiopathic nature. Typically, in the vast majority of cases it occurs at younger age.
2. Type 2 diabetes characterized by a relative insulin deficiency coupled with an insulin
resistance state. It includes over 90% the diabetic states developing after middle age.
This diabetic state is often seen in people with visceral obesity and metabolic syndrome.
3. Gestational diabetes developing during pregnancy and in most cases disappearing after
delivery. 60-70% of these patients will progress to diabetes during their life.
4. Other particular forms of diabetes include the clinical conditions secondary to diseases
of exocrine pancreas (inflammation, trauma, neoplasm, and pancreatectomy) and
endocrine system (Syndrome Cushing, phaeochromocytoma, acromegalia). It also
includes genetic defects of beta cells and drug-induced diabetic states, such as those
trigged by cortisone, antidepressants, beta-blockers and thiazide diuretics.
The clinical classification is based on criteria proposed by the WHO in 1999. In addition, The
American Society of Diabetology (ADA, 2003.). The WHO recommendations for
www.intechopen.com
The Importance of Risk Factors Analysis in the Prevention of Cardiovascular Disease (CVD) 17
glucometabolic classification based on measuring both fasting and two hour post-load
glucose concentrations and recommend that a standardized 75g glucose tolerance test
(OGTT) should be performed in the absence of overt hyperglycaemia. Glycated
haemoglobin (HBA1c) is useful measure of metabolic control and the efficacy of glucose
lowering treatment in people with diabetes. It presents a mean value of blood glucose
during the preceding six to eight weeks (life span of erythrocytes). HBA1c not
recommended as a diagnostic test for diabetes. Because normal values do not exclude
diabetes or impaired glucose tolerance. The approach for early detection of diabetes and
people in risk of acquiring diabetes is measuring of blood glucose in people who are at risk
due to their demographic and clinical characteristics. Collecting questionnaire-based
information on etiological factors for type 2 diabetes is necessary. Glycaemia testing (OGTT)
is always necessary as a secondary step to accurately defined impaired glucose homeostasis.
Glucometabolic abnormalities are common in patients with CVD and an OGTT should carry
out in them. In the general population the appropriate strategy is to start with risk
assessment as the primary screening tool combined with subsequent glucose testing (OGTT)
of individuals identified to be at high risk. The relationship between hyperglycaemia and
CVD should be seen as continuum. For each 1% increase of HBA1c there is defined
increased risk for CVD. The risk of CVD for people with overt diabetes increased by two to
three times for men and three to five times for women compared with people without
diabetes. In type 1 diabetic patients prevalence of CVD amounts to 10% with a pronounced
increase when diabetic nephropathy is detected. In type 2 diabetic patients prevalence of
CVD is higher and almost similar to that displayed by patients with history of a previous
myocardial infarction. Cardiovascular complications have a higher adverse impact on
mortality in type 2 than type 1 diabetes (55% vs. 44%). It is still debated whether
asymptomatic hyperglycaemia is associated with an increased risk of coronary events.
Information on post-prandial (post-load) glucose also predicts increased cardiovascular risk
in subjects with normal fasting glucose levels. The most common cause of death in adults
with diabetes is CVD. Their risk is two to three times higher than that among people
without diabetes. The combination of type 2 diabetes and previous CAD identifies patients
with particularly high risk for coronary deaths. The relative effect of diabetes is lager in
women than men (Table 3).
Elevated 2-hour post-load plasma glucose has much bigger impact on cardiovascular risk
than fasting glucose. For major cardiovascular risk factors, mortality and cardiovascular
morbidity are predicted by hyperglycaemia itself. Elevated blood glucose levels have an
adverse impact on cardiovascular risk profile by decreasing vascular function (in particular
endothelial function) and reducing nitric oxide bioavailability.
www.intechopen.com
18 Atherosclerotic Cardiovascular Disease
International Diabetes Federation-Metabolic Syndrome Definition
Central Obesity (defined as waist circumference > 94 cm for European men and >80 cm
for European women, with ethnicity specific values for other groups).
In addition, any two of the following four factors:
www.intechopen.com
The Importance of Risk Factors Analysis in the Prevention of Cardiovascular Disease (CVD) 19
- Raised TG level :> 1.7 mmol/L (150 mg/dl), or specific treatment for this lipid
abnormality.
- Reduced HDL cholesterol :< 1.0 mmol/L (40 mg/dl) in males and < 1.2 mmol/L (50
mg/dl) in females, or specific treatment for this lipid abnormality.
- Raised blood pressure: systolic BP >130 or diastolic BP >85 mmHg, or treatment of
previously diagnosed hypertension.
- Raised fasting plasma glucose (FPG)> 5.6 mmol/L (100mg/dl) or previously diagnosed
type 2 diabetes.
If glucose level is above 5.6 mmol/L or 100mg/dl, OGTT is strongly recommended but is
not necessary to define presence of the syndrome.
Compared to the opinions expressed by other Guidelines and Scientific Societies, the
European Guidelines seem to take a conservative position on the clinical impact of
cardiovascular risk profile in patients with metabolic syndrome. This is partially because the
two Societies are still waiting for further evidence.
The diabetogenic risk of patients with CVD is super imposable to the one characterizing
subjects with obesity or metabolic syndrome. Patient with a high cardiovascular risk a
glucose intolerance state may be responsible for the elevated prevalence of sudden death.
Adequate control of postprandial hyperglycaemia has a favourable impact on
cardiovascular and all-cause mortality. The elevated cardiovascular risk profile displayed by
the diabetic patient depends not only on the glycaemia (and insulin) abnormality but also,
and largely, on the development and progression of the atherogenic vascular process. The
mechanisms include oxidative stress, the dyslipdemic state and the pro-atherogenic process.
1. Oxidative stress represents one of the cornerstones of the endothelial dysfunction as
well as of the atherogenic process, but clinical studies are still inconclusive on this issue
and do not to clarify whether and to what extent anti-oxidative drugs have a favourable
therapeutic impact on the atherosclerotic process.
2. Dyslipidaemic state - lipid disorders classically described in diabetes include a elevated
triglycerides and LDL and decreased HDL levels. Recent evidences support the role of
free fatty acids (whose plasma concentrations increased in diabetes) in favouring the
atherogenic process. Along with free fatty acids, another proatherogenic factor is the
accumulation of triglyceride-rich lipoproteins, due to a reduced clearance by
lipoprotein lipases.
3. Pro-atherogenic process and thrombosis - hyperglycaemia and insulin resistance exert
adverse effects on thrombosis and coagulation by altering platelet function. Key
features of the altered thrombosis process are the increased expression of glycoproteins,
overproduction of fibrinogen, thrombin and von Willebrand factor as well as the
reduction in endogenous anticoagulants (thrombomodulin and protein C).
4. The pathophysiological alterations responsible for the increased atherogenic risk,
typical of the diabetic state are multifaceted. Several of these alterations are shared by
the metabolic syndrome, which also includes glycaemia abnormalities as a key patho-
physiological feature.
Diabetes doubles the probability of developing CHD or a cardiovascular disease in general.
Death from the consequences of CHD increases by a factor of four to six. Next to occlusive
diseases of the vessels of the lower extremities, (peripheral arterial occlusive vascular
disease) coronary heart disease is the most frequent complication in diabetes. The presence
of additional risk factors, such as obesity, lipometabolic disorders, high blood pressure or
smoking, endangers diabetics more than any other patient group.
www.intechopen.com
20 Atherosclerotic Cardiovascular Disease
Unfortunately, a great deal is still unclear regarding the effects of diabetes on the
development and course of CHD.
www.intechopen.com
The Importance of Risk Factors Analysis in the Prevention of Cardiovascular Disease (CVD) 21
www.intechopen.com
22 Atherosclerotic Cardiovascular Disease
active. Regular physical activity, whether pursuing a sport or just in the form of working in
the garden, improves the heart muscle oxygenation its function, delays ageing of the vessels
and protects against cardiac arrhythmias. The duration, intensity and frequency of the
activity must be sufficient to achieve a training effect.
Physical exercise also has a beneficial effect on other risk factors: reduced weight, improved
glucose tolerance in diabetes and normalized blood lipid and lowering of blood pressure.
People with risk factors for CHD who have previously not undertaken any sports should
only do so after advice from a physician because unaccustomed exertion in the presence of
underlying CHD can lead to sudden cardiac death.
www.intechopen.com
The Importance of Risk Factors Analysis in the Prevention of Cardiovascular Disease (CVD) 23
www.intechopen.com
24 Atherosclerotic Cardiovascular Disease
recurrent events, including death, myocardial infarction, and restenosis after percutaneous
coronary intervention (PCI). The benefits of therapy based on this strategy remain uncertain.
Hs-CRP levels, using standardized assays, should categorize patients into one of three
relative risk categories: low risk < 1.0mg/L; average risk 1.0-3.0 mg/L; high risk > 3.0mg/L.
Measurement of hs-CRP should be done twice (averaging results), optimally two weeks
apart, fasting or no fasting in metabolically stable patients. If hs-CRP level is > 10mg/L, the
test should repeat and the patient examined for sources of infection or inflammation. The
entire adult population should not screen for hs-CRP for cardiovascular risk assessment, not
should hs-CRP levels used to determine preventive measures for secondary prevention or
for patients with acute coronary syndromes. CRP was relatively moderate predictor of CVD
risk an added only marginally to the prediction of CVD risk based on established risk
factors.
2.10 Fibrinogen
Increased plasma fibrinogen is a risk factor because it increases blood viscosity and platelet
aggregation and promotes thrombogenesis. More over fibrinogen is the acute phase
reactant, and serves as a marker of inflammation, an important component of atherogenesis.
Plasma fibrinogen influences platelet aggregations and blood viscosity, interacts with
plasminogen binding and in combination with thrombin, mediates the final step in clot
formation and the response to vascular injury. In addition, fibrinogen associates positively
with age, obesity, smoking cigarettes, diabetes and LDL-cholesterol level and inversely with
HDL-cholesterol level, alcohol use physical activity and exercise level. Fibrinogen level, like
CRP, an acute phase reactant, increases during inflammatory responses. Studies found no
significant positive associations between fibrinogen levels and future risk of cardiovascular
events.
2.11 Imunoreactivity
Imunoreactivity could also be an important factor in the development of endothelial
damage and thus atherosclerosis development. It is supported by the finding of the
accumulated lipids in the affected arterioles of patients with dermatomyositis, systemic
lupus erythematosus, scleroderma and rheumatoid arthritis. Atherosclerosis is more
common after the transplantation of organs; it also explains the deposition of immune
complexes in the walls of arteries and their damage.
2.12 Homocysteine
Increased homocysteine level is also a risk factor for atherosclerosis. People with levels of
homocysteine higher than 12 mmol/L have twice the risk of myocardial infarction
regardless of sex. Homocysteine acts proatherogenically because it changes the function of
the endothelium and promotes the oxidation of LDL.
Homocysteine is a sulfhydryl-containing amino acid derived from the demethylastion of
dietary methionine. Patient with rare inherited defects of methionine metabolism can
develop severe hyperhomocysteinemia (plasma level >100μmol/L) and have markedly
elevated risk of premature atherothrombosis as well as venous thromboembolism. The
mechanisms that account for these effects remain uncertain but include endothelial
dysfunction, accelerated oxidation of LDL-cholesterol, impairment of flow-mediated
endothelial-derived relaxing factor with subsequent reduction in arterial vasodilatation,
www.intechopen.com
The Importance of Risk Factors Analysis in the Prevention of Cardiovascular Disease (CVD) 25
2.13 Albuminuria
Albuminuria is a result of kidney glomerular damage; increased albuminuria indicates a
higher risk of progression of kidney disease. Hypertension and albuminuria are
independent factors affecting long-term reduction of kidney function. Renal disease is both
a cause and consequence of hypertension. Treating arterial hypertension reduces
cardiovascular risk and risk of kidney damage. Reducing albuminuria also reduces total
cardiovascular risk and kidney damage.
2.14 Hyperuricemia
Hyperuricemia is a high value of serum uric acid in blood: higher of 360 μmol/L (6 mg/dl)
for women and 400 μmol/L (6.8 mg/dl) for men. It has double effect: damages the
endothelium and smooth muscle cells of blood vessels and acts as an oxidant. Epidemiologic
study found an association between hyperuricemia and hypertension, renal disease and
CVD.
www.intechopen.com
26 Atherosclerotic Cardiovascular Disease
Male sex is a risk factor that has been proven in numerous epidemiological studies,
regardless of the higher incidence of other risk factors in men than in women. It known that
the atherosclerotic changes, especially coronary arteries and blood vessels, come about 10
years later in women than in men. This is partly explained by the beneficial effects of
estrogen on lipoproteins, because they increase HDL-cholesterol and reduce LDL-
cholesterol and Lp(a), oxidation LDL-cholesterol, fibrinogen and homocysteine. Sex
hormones may have direct effects on blood vessels because existence of receptors for
androgens and estrogens on smooth muscle cells of the blood vessels has been proven. Even
after menopause, cardiovascular risk is still significantly lower in women than in men of the
same age. Nevertheless, in most developed countries cardiovascular diseases are the major
causes of mortality in women, not only in men.
3.1.3 Age
The risk of developing coronary heart disease and suffering myocardial infarction increases
with age for both sexes. However, atherosclerosis does not however begin abruptly. The
signs of incipient coronary atherosclerosis can be apparent from a very early stage. Studies
have shown that atherosclerotic transformation processes of aorta can become apparent
even in three years old children. Thus, the coronary vessels are involved in this process from
in patient’s youth (20 or 30 years). Although age is an important factor, the probability of
developing coronary heart disease varies according to the presence of the additional risk
factors. The best estimate of the individual’s risk is therefore provided by consideration of
age in relation to other risk factors present. The observation that significant atherosclerotic
changes in the coronary vessels can start very early in life emphasizes the need for
prevention at an early stage.
www.intechopen.com
The Importance of Risk Factors Analysis in the Prevention of Cardiovascular Disease (CVD) 27
4. Conclusion
There is no doubt that patients with CVD and those with multiple risks factors deserve
attention to the term you have particular risk factors extensively and persistently treated. All
previous population studies indicate, despite a large palette of new drugs with proven
usefulness, many patients who have survived a CVD incident continue smoking, remain
overweight, and are treated unsatisfactory. Failure to treat high blood pressure and other
risk factors is partly explained by the fact that these patients often simultaneously take
several medications with potential side effects. One solution is fixed combination of drugs
for treating hypertension, dislipidaemia and diabetes.
CVD prevention refers to all measures taken to prevent their occurrence. It must be carried
out in patients who already have documented CVD (coronary disease, previous AMI,
stroke, transient ischemic attack, peripheral arteries atherosclerotic disease), hence called the
secondary prevention. Primary prevention refers to preventing and treating risk factors in
people who have one or more risk factors, but no clinical signs of CVD. Evaluation of the
total risk burden is always needed in primary and secondary prevention, and cannot be
limited to only one risk factor. Epidemiological studies have proven that many people with
an increased risk of CVD, have several risk factors simultaneously, which poses significant
challenge to physician.
www.intechopen.com
28 Atherosclerotic Cardiovascular Disease
Table 4. Relative risk chart (reproduced from 2004. European guidelines on cardiovascular
disease prevention in clinical practice, Croatian Society of Cardiology)
www.intechopen.com
The Importance of Risk Factors Analysis in the Prevention of Cardiovascular Disease (CVD) 29
Table 5. Stratification of CV Risk in four categories. SBP: systolic blood pressure; DBP:
diastolic blood pressure; CV: cardiovascular; HT: hypertension. Low,moderate, high and
very high risk refer to 10 year risk of a CV fatal or non-fatal event. OD: subclinical organ
damage; MS: metabolic syndrome. (Reproduced from 2007.European Guidelines for the
management of arterial hypertension, Croatian Society of Hypertension).
Using the SCORE charts, we can assess CVD risk in asymptomatic persons as follows (Table
5, Table 6):
1. use the low risk chart in Belgium, France, Italy, Greece, Luxemburg, Spain, Switzerland
and Portugal; use the high risk chart in other countries in Europe
2. Find the cell nearest to the person’s age, cholesterol and blood pressure (PB) values,
bearing in mind that risk will be higher as the person approaches the next age,
cholesterol or BP category
3. Check the qualifiers
4. Establish the total 10-year risk for fatal CVD
Note that a low total cardiovascular risk in a young person may conceal a high relative risk;
this may explain to the person by using the relative risk chart. As the person’s ages, a high
relative risk will translate into a high total risk. More intensive lifestyle advice will need in
such persons.
People who stay healthy tend to have certain characteristics:
0 no tobacco
3 walk 3 kilometres daily or 30 minutes any moderate activity
5 portions of fruit and vegetables a day
140 Blood pressure less than 140 systolic
5 total blood cholesterol < 5mmol/L
3 LDL-cholesterol< 3mmol/L
0 avoidance of overweight and diabetes
Continuous training program of the total population in the prevention of risk factors and
therefore coronary heart disease, one of the most common causes of morbidity and mortality
in developed countries of Europe is mandatory.
www.intechopen.com
30 Atherosclerotic Cardiovascular Disease
Education should start in the younger age groups to prevent the emergence of risk factors,
encourage proper diet and lifestyle changes, primarily in the populations who have high
total cardiovascular risk. Considering increasing incidence of CVD in rapidly ageing
population, prevention is the only way to overcome CVD in the future.
Table 5. 10-year risk of fatal CVD in low risk regions of Europe (reproduced from 2004.
European guidelines on cardiovascular disease prevention in clinical practice, Croatian
Society of Cardiology)
www.intechopen.com
The Importance of Risk Factors Analysis in the Prevention of Cardiovascular Disease (CVD) 31
Table 6. 10-year risk of fatal CVD in high-risk regions of Europe (reproduced with
permission from 2007. European guidelines on cardiovascular disease prevention in clinical
practice, Croatian Society of Cardiology)
5. References
Harrison, T.R. (2008). Harrison s Principles of Internal medicine, Single edition book, ISBN
978-0-07-159991-7, New York, USA
Ballantyne, C.M.; Keefe, O. Jr. & Gotto, A.M. (2007). Dyslipidemia essentialis, Physican, s
Press, ISBN 1-890114-65-0, Michigan, USA
Petrač, D. (2009). Interna medicina, Medicinska naklada, ISBN 978-953-176-391-2, Zagreb,
Croatia
McGorrian, C. (2011).Estimating modifiable coronary heart disease risk multiple regions of
the world: the INTERHEART Modifiable Risk Score, European Heart Journal, The
Zurich Heart House, ISNN 0195-668X; Zurich, Switzerland
Vahanian, A., Ferrari, R. (2010). Compendum of abridged ESC guidelines 2010, Springer
Healthcare, ISBN 978-1-907673.9, London, UK.
www.intechopen.com
32 Atherosclerotic Cardiovascular Disease
National Institut of Clinical Excellence (NICE), (August 2004). Clinical Guideline 18,
Hypertension: management of hypertension in adults in primary care. NICE
London, UK, www.nice.org.uk/CG018NICEguideline.
National Institut of Clinical Exellence (NICE), (March 2010).Quick reference guide, Lipid
modification- Cardiovascular risk assessment and modification of blood lipids for
the primary and secondary prevention of cardiovascular disease, NICE London,
UK,www.niceorg.uk/CG67
Pesek, K. & Pesek, T. (2007). The prevalence of cardiovascular disease risk factor in patient
from Croatian Zagorje County treated in Department of Internal medicine General
Hospital Zabok from 2000-2006y. Collegium Antropologicum, 31,/Septembar
2007), pp.709-15,ISSN 0350-6134
Pesek, K. & Pesek, T. (2008). Risk Factors Analysis and Diagnoses of Coronary Heart Disease
in Patients with Hypercholesterolemia from Croatian Zagorje County, Collegium
Antropologicum,32,(April 2008),pp.369-74,ISSN 0350-6134
Hrvatsko kardiološko društvo (HKD), (2004). Europske smjernice za prevenciju bolesti srca i
krvnih žila u kliničkoj praksi, Zagreb, Croatia, www.kardio.hr,www.escardio.org
Hvatsko društvo za hipertenziju (HDH), Hrvatsko kardiološko društvo (HKD), (2007).
Smjernice za dijagnosticiranje I liječenje arterijske hipertenzije, Zagreb, Croatia,
www.kardio.hr www.hdh.hr, www.escardio.org
www.intechopen.com
Atherosclerotic Cardiovascular Disease
Edited by Dr. Ksenija Pesek
ISBN 978-953-307-695-9
Hard cover, 124 pages
Publisher InTech
Published online 03, October, 2011
Published in print edition October, 2011
Cardiovascular diseases (CVD) are still one of the leading causes of death in the world. The book
Atherosclerotic Cardiovascular Disease is a contribution to the application of new knowledge in the area of
cardiovascular diseases. The book comprises six chapters divided in three subsections, starting with the
General Considerations of Cardiovascular Disease, through Diagnostic Techniques, and Specific Therapy.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Ksenija Pešek, Tomislav Pešek and Siniša Roginić (2011). The Importance of Risk Factors Analysis in the
Prevention of Cardiovascular Disease (CVD), Atherosclerotic Cardiovascular Disease, Dr. Ksenija Pesek (Ed.),
ISBN: 978-953-307-695-9, InTech, Available from: http://www.intechopen.com/books/atherosclerotic-
cardiovascular-disease/the-importance-of-risk-factors-analysis-in-the-prevention-of-cardiovascular-disease-
cvd-